Table 1: Comparison between RMST and median according to the survival curves of the KEYNOTE-189 trial.
|
|
Results (months) |
|||
|
Pembrolizumab |
Placebo |
Gain |
||
|
- Overall survival |
RMST |
19.92 |
14.50 |
5.42 |
|
median |
22.0 |
10.7 |
11.3 |
|
|
- Progression-free survival |
RMST |
15.19 |
10.34 |
4.85 |
|
median |
9.0 |
4.9 |
4.1 |
|